Astex uses its fragment based drug discovery technology to identify and develop new medicines, primarily for the treatment of cancer and antiviral diseases. The company has a number of internally developed therapeutic candidates in clinical trials. Astex merged with SuperGen in July 2011 and was acquired by Otsuka Pharma for $860 million in September 2013.
Location: United Kingdom, England, Cambridge
Member count: 51-200
Total raised: $150K
Founded date: 1999
Investors 2
| Date | Name | Website |
| - | Industry V... | industryve... |
| - | Abingworth... | abingworth... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 04.05.2022 | - | $150K | - | - |
Mentions in press and media 8
| Date | Title | Description | Category | Author | Source |
| 31.12.2022 | Astex Co-f... | CAMBRIDGE, United Kingdom, Dec... | - | - | einpresswi... |
| 31.12.2022 | Astex Co-f... | /EIN News/ -- CAMBRIDGE, Unite... | - | - | einpresswi... |
| 13.01.2021 | Taiho and ... | Taiho and Astex extend strateg... | - | - | cambridgen... |
| 08.07.2019 | LeadXpro t... | Recent years have seen a rev... | Background... | - | startuptic... |
| 07.06.2019 | Astex Phar... | Astex Pharmaceuticals and Otsu... | - | - | cambridgen... |
| 16.03.2018 | Astex cont... | Astex continues to deliver in ... | - | - | cambridgen... |
| 21.11.2016 | Astex Phar... | Astex Pharmaceuticals, a Cambr... | UK | - | finsmes.co... |
| 12.10.2015 | Dementia C... | Dementia Consortium signs new ... | - | - | cambridgen... |